Cardiovascular Complications of Novel Multiple Myeloma Treatments
Case presentation: A 75-year-old woman was referred to cardiology for optimization of cardiovascular risk factors before starting a new cancer treatment. She was diagnosed with IgG-κ multiple myeloma (MM) 2 years previously that progressed after her previous treatments. Her medical history also included type 2 diabetes mellitus, hypertension, and a remote history of deep vein thrombosis treated with a “blood thinner” for 6 months. Her hematologist has determined that a combination of carfilzomib, lenalidomide, and dexamethasone is the best treatment option for this patient but is concerned about the risk of cardiovascular complications from the new treatment and wants the patient to undergo evaluation by a cardiologist.
Circulation
In The News
American Society of Hematology 2016 Annual Meeting
Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
American Society of Hematology 2016 Annual Meeting
Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy
American Society of Hematology 2016 Annual Meeting
Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
American Society of Hematology 2016 Annual Meeting
Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
In The Literature
Bone Marrow Transplant